Cure My Disease

Don't miss your cure!

 Log in / Sign up

New blood test could end Trial-and-Error for arthritis drugs

NCT ID NCT07150000

Diagnosis Sponsor: University of Bonn Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study is testing a new blood-based test that aims to predict which medication will work best for each person with rheumatic diseases like rheumatoid arthritis or lupus. Researchers will take a blood sample and analyze immune cells to create a personalized treatment profile. If successful, this could replace the current trial-and-error approach, helping patients find effective treatment faster.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Ex vivo diagnostic assay using patient blood cells
What this could lead to
If successful, this could give doctors a simple blood test to pick the right drug for each patient, speeding up relief and reducing side effects.
What could go wrong
This is an early-stage study (120 participants) testing a lab assay, not a treatment. The test may not accurately predict real-world responses or work for all rheumatic diseases.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 120 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2025

Expected to finish

Dec 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Participants will be recruited from the outpatient rheumatology clinic at the University Hospital Bonn. The study population includes adult patients (≥ 18 years) with a confirmed diagnosis of an autoimmune or autoinflammatory rheumatic disease, including: rheumatoid arthritis (RA), psoriatic arthritis (PsA), axial spondyloarthritis (axSpA), giant cell arteritis (GCA), connective tissue diseases \[systemic lupus erythematosus (SLE), systemic sclerosis (SSc), mixed connective tissue disease (MCTD), idiopathic inflammatory myopathies (IIM)\], ANCA-associated vasculitides \[microscopic polyangiitis (MPA), granulomatosis with polyangiitis (GPA), eosinophilic granulomatosis with polyangiitis (EGPA)\], and autoinflammatory disorders. In addition, age- and sex-matched healthy controls without known rheumatologic conditions will be included for comparative analysis. All participants must be able and willing to provide informed cons

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Participants aged ≥ 18 years * Signed written informed consent to participate voluntarily in the study. * Confirmed diagnosis (by the treating physician) of one of the following autoimmune or autoinflammatory rheumatic diseases: * Rheumatoid arthritis (RA) * Psoriatic arthritis (PsA) * Axial spondyloarthritis (axSpA) * Giant cell arteritis (GCA) * Connective tissue diseases, including: 1. Systemic lupus erythematosus (SLE) 2. Systemic sclerosis (SSc) 3. Mixed connective tissue disease (MCTD) 4. Idiopathic inflammatory myopathies (IIM) * ANCA-associated vasculitides (AAV), including: 1. Microscopic polyangiitis (MPA) 2. Granulomatosis with polyangiitis (GPA) 3. Eosinophilic granulomatosis with polyangiitis (EGPA) * Autoinflammatory diseases, including 1. Familial Mediterranean fever (FMF) 2. Cryopyrin-associated periodic syndromes (CAPS) 3. TNF receptor-associated periodic syndrome (TRAPS) 4. Adult-onset Still's disease (AOSD) Exclusion Criteria: * Refusal to participate in the study or inability to provide informed consent. Inclusion Criteria - Healthy Control Group: * Participants aged ≥ 18 years (capable of providing informed consent). * Signed written informed consent to participate voluntarily in the study. Exclusion Criteria - Healthy Control Group: \- Presence of a known or active rheumatologic disease.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANCA associated vasculitis (AAV) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

ankylosing spondylitis anti-neutrophil cytoplasmic antibody-associated vasculitis Arthritis, Gouty autoinflammatory syndrome connective tissue disorder Giant Cell Arteritis gout granulomatosis with polyangiitis idiopathic inflammatory myopathy myositis disease polymyalgia rheumatica psoriatic arthritis rheumatic disorder rheumatoid arthritis systemic lupus erythematosus systemic sclerosis temporal arteritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ANCA associated vasculitis (AAV) Autoinflammatory disease Axial spondylarthritis (axspa) Connective tissue disease (CTD) Giant cell arteritis (GCA) Gout arthritis Idiopathic inflammatory myopathy (IIM) Polymyalgia rheumatica (PMR) Psoriatic arthritis (PSA) Rheumatic diseases Rheumatoid arthritis (RA) Systemic lupus erthematosus (SLE) Systemic sclerosis (SSC)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • University Hospital, Bonn

    RECRUITING

    Bonn, North Rhine-Westphalia, 53127, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.